# DUO-O (NCT03737643)

> Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03737643
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Advanced Ovarian Cancer
- Interventions: Bevacizumab; Durvalumab; Olaparib; Placebo olaparib; Durvalumab placebo; Carboplatin+Paclitaxel
- Enrollment: 1407
- Primary outcome: Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - Full Analysis Set
- Primary outcome: Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - (Full Analysis Set, HRD Positive)

## Commentary we found

- YouTube: 36
- Podcasts: 21
- X threads: 20
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=duo-o-nct03737643

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03737643", "email": "<work email>"}; the inbox owner confirms by the emailed link.